Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
A recent prospective meta-analysis demonstrated that interleukin-6 antagonists are associated with lower all-cause mortality in hospitalised patients with COVID-19, compared with usual care or placebo. However, emerging evidence suggests that clinicians are favouring the use of tocilizumab over sarilumab. A new randomised comparison of these agents from the REMAP-CAP trial shows similar effects on in-hospital mortality. Therefore, we initiated a network meta-analysis, to estimate pairwise associations between tocilizumab, sarilumab and usual care or placebo with 28-day mortality, in COVID-19 patients receiving concomitant corticosteroids and ventilation, based on all available direct and indirect evidence.
Methods
Eligible trials randomised hospitalised patients with COVID-19 that compared tocilizumab or sarilumab with usual care or placebo in the prospective meta-analysis or that directly compared tocilizumab with sarilumab. Data were restricted to patients receiving corticosteroids and either non-invasive or invasive ventilation at randomisation.
Pairwise associations between tocilizumab, sarilumab and usual care or placebo for all-cause mortality 28 days after randomisation were estimated using a frequentist contrast-based network meta-analysis of odds ratios (ORs), implementing multivariate fixed-effects models that assume consistency between the direct and indirect evidence.
Findings
One trial (REMAP-CAP) was identified that directly compared tocilizumab with sarilumab and supplied results on all-cause mortality at 28-days. This network meta-analysis was based on 898 eligible patients (278 deaths) from REMAP-CAP and 3710 eligible patients from 18 trials (1278 deaths) from the prospective meta-analysis. Summary ORs were similar for tocilizumab [0·82 [0·71–0·95, p = 0·008]] and sarilumab [0·80 [0·61–1·04, p = 0·09]] compared with usual care or placebo. The summary OR for 28-day mortality comparing tocilizumab with sarilumab was 1·03 [95%CI 0·81–1·32, p = 0·80]. The p-value for the global test of inconsistency was 0·28.
Conclusions
Administration of either tocilizumab or sarilumab was associated with lower 28-day all-cause mortality compared with usual care or placebo. The association is not dependent on the choice of interleukin-6 receptor antagonist.
Article activity feed
-
-
SciScore for 10.1101/2021.08.26.21262523: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: All included trials secured institutional review board approval, and informed consent for participation in each trial was obtained, consistent with local institutional review board requirements.
Consent: All included trials secured institutional review board approval, and informed consent for participation in each trial was obtained, consistent with local institutional review board requirements.Sex as a biological variable not detected. Randomization Eligible randomized trials that aimed to compare tocilizumab or sarilumab with standard care in the treatment of hospitalized patients with COVID-19 were identified from the searches conducted by the same authors for a recently published … SciScore for 10.1101/2021.08.26.21262523: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: All included trials secured institutional review board approval, and informed consent for participation in each trial was obtained, consistent with local institutional review board requirements.
Consent: All included trials secured institutional review board approval, and informed consent for participation in each trial was obtained, consistent with local institutional review board requirements.Sex as a biological variable not detected. Randomization Eligible randomized trials that aimed to compare tocilizumab or sarilumab with standard care in the treatment of hospitalized patients with COVID-19 were identified from the searches conducted by the same authors for a recently published systematic review and prospective meta-analysis1. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources All analyses were conducted in Stata statistical software version 16.1 [StataCorp, USA] using the ‘network’ user-written command suite14. Stata statisticalsuggested: NoneStataCorpsuggested: (Stata, RRID:SCR_012763)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:This study has a few limitations. First, these results are focused on patients treated with corticosteroids and NIV, IMV or ECMO alongside interleukin-6 receptor antagonists, and so may not generalize to less critically ill patients. Second, only five of the included trials have been published in peer-reviewed journals, with the remaining either currently available as pre-print publications or currently unpublished. Third, the direct evidence in each of the three comparisons included in this network meta-analysis came predominantly from a single trial (either RECOVERY, REGENERON-P3 or REMAP-CAP), with these three trials primarily conducted in high income countries. In conclusion, this network meta-analysis of clinical trials of hospitalized patients with COVID-19 receiving ventilation and corticosteroids at randomization, confirms that administration of tocilizumab or sarilumab, compared with usual care or placebo, is associated with similarly lower 28-day all-cause mortality.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-